Inhibikase Therapeutics share price today

Inhibikase Therapeutics, Inc.'s share price was $1.56 at the close on 4 November 2026. That is 19.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between $1 and $3, and at that close it sat 7% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 6 weeks running.

Over the last 1 year the share price moved −16% while the S&P 500 moved +23%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 25 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Inhibikase Therapeutics, Inc. pays no dividend. In the last 11 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Inhibikase Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Inhibikase Therapeutics, Inc. posted a net loss of $4.2 M in the Dec 2023 quarter. The full FY23 year was a loss of $19.0 M. The same quarter a year earlier lost $4.3 M. 11 of the last 11 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Inhibikase Therapeutics, Inc. reported $0 of revenue in the Dec 2023 quarter, −100.0% on the same quarter a year earlier. Over 2 years it has grown −71.0% a year on average. The last full year, FY23, came in at $261 K. The last four reported quarters add to $261 K.

Revenue is everything the company billed its customers in the period.

FY23 revenue was $261 K, +112.2% on the year before.

Recent pace: the last four quarters grew +635.3% on average, against −71.0% a year over the longer run, so this year is growing faster than its own long-run rate.

Inhibikase Therapeutics, Inc.'s sales have fallen to very little: FY23 revenue was $261 K, against $3.1 M in FY21. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover.

Inhibikase Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY23 its operations used $18.1 M of cash, against −$19.0 M of profit. After $14.0 K of spending on assets, free cash was −$18.1 M: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Inhibikase Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $257 K on assets over the last 2 years. Averaged over those years that is 49.2% of FY23 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $257 K over the last 2 years.

In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it.

Inhibikase Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Inhibikase Therapeutics, Inc. at 1,091.8× its FY23 revenue of $261 K. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Inhibikase Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 7 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Inhibikase Therapeutics, Inc. earned a ROE of −173% in FY23. Its return on capital used (ROIC) is left out: on sales this small it reads −36%, a number that says nothing useful about the business.

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Inhibikase Therapeutics, Inc. has total debt of $38.0 K against shareholder equity of $80.1 M as of Jun 2025, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.00 in FY24. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

18.3% of Inhibikase Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 29.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Inhibikase Therapeutics, Inc., the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

There is no score against its industry: Inhibikase Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Inhibikase Therapeutics is the 177th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Ocugen, Inc., SAB Biotherapeutics, Inc. and Fulcrum Therapeutics, Inc. Just below it: Q32 Bio Inc., Bicycle Therapeutics plc and Lineage Cell Therapeutics, Inc.

Biotechnology companies close in size

174. Ocugen, Inc. $297 million
175. SAB Biotherapeutics, Inc. $289 million
176. Fulcrum Therapeutics, Inc. $288 million
177. Inhibikase Therapeutics, Inc. $285 million
178. Q32 Bio Inc. $267 million
179. Bicycle Therapeutics plc $261 million
180. Lineage Cell Therapeutics, Inc. $260 million

All 211 Biotechnology companies, largest first

Companies close in size in other industries

3219. Matrix Service Company $270 million · Engineering & Construction
3220. Western New England Bancorp, Inc. $270 million · Banks - Regional
3221. Inhibikase Therapeutics, Inc. $269 million
3222. Omega Flex, Inc. $268 million · Specialty Industrial Machinery
3223. Alight, Inc. $268 million · Software - Application

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.